Stay ahead in the booming mRNA market, projected to reach $63.28 billion by 2025, with the 3 rd mRNA Process Development & Manufacturing Summit 2025 - Europe’s premier industry-focused forum dedicated ...

The clinical potential of mRNA was revealed with COVID-19 vaccines, but that was just the beginning. “Today, this Nobel prize–winning technology is being leveraged for many therapeutic applications, ...

Learn from the MHRA about evolving CMC expectations, submission criteria, and initiatives for streamlining approval routes for mRNA platforms. Continuous processing: Optimizing efficiency & ...

From global vaccines to personalized cancer therapies, mRNA is being considered across several clinical applications, which ultimately creates varying requirements in terms of production scale and ...

The market for mRNA vaccines has experienced a surge fueled by the global rollout of the COVID-19 vaccines, and the potential of mRNA technology in public health opens a new frontier in medical ...

RIO RANCHO, N.M.--(BUSINESS WIRE)--Nature’s Toolbox (NTx), a life sciences company developing next-generation platforms for RNA and protein manufacturing, today launched NTx Services. This new service ...

LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a ...

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m(1) TP). The ...

Leveraging its integrated "design-synthesis-quality control" system, Creative Biolabs is overcoming bottlenecks in mRNA ...

- Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc.